Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenoceptor antagonist that preferentially binds to α1A receptors in the prostate and bladder neck, causing smooth muscle relaxation and improved urinary flow.
## Primary Indications
* Treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
* Off-label: Expulsive therapy for ureteral calculi (distal stones).
## Adult Dosing
* **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day.
* **Maximum Dose:** 0.8 mg daily. If 0.4 mg is ineffective after 2–4 weeks, it may be increased to 0.8 mg.
* **Off-label (Ureteral Stones):** 0.4 mg daily for up to 4 weeks.
## Pediatric Dosing
* **Safety/Efficacy:** Not FDA-approved for pediatric use.
* **Off-label:** Sometimes used in pediatric urology for dysfunctional voiding or ureteral stones under specialist supervision; dosing is weight-based or empiric, though no standard pediatric dosing guidelines are universally established. Consult institutional pediatric protocols.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment necessary for mild-to-moderate impairment. Use with caution in severe renal impairment (CrCl <10 mL/min).
* **Hepatic Impairment:** No dose adjustment for mild-to-moderate impairment. Not studied in severe hepatic impairment (Child-Pugh Class C); avoid use.
* **CYP3A4 Inhibition:** Reduce dose or avoid if co-administered with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin).
## Contraindications
* Hypersensitivity to tamsulosin.
* History of orthostatic hypotension.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde/decreased), rhinitis, fatigue.
* **Serious:** Orthostatic hypotension (risk highest with first dose), syncope, Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery, priapism (rare), angioedema.
## Key Drug Interactions
* **CYP3A4/2D6 Inhibitors:** May significantly increase plasma concentrations of tamsulosin.
* **Antihypertensives/PDE-5 Inhibitors:** Enhanced hypotensive effect; monitor for postural hypotension or syncope.
* **Alpha-blockers:** Concomitant use with other alpha-blockers is generally contraindicated due to additive side effects.
## Monitoring
* **Blood Pressure:** Monitor for orthostasis and hypotension, especially after the first dose or dose escalation.
* **BPH Symptoms:** Evaluate improvements in urinary flow and symptoms via standardized scores (e.g., AUA-SI).
* **Cataract Surgery:** Patients should inform their ophthalmologist of current or past tamsulosin therapy due to IFIS risk.
## Clinical Pearls
* **Administration:** Must be taken 30 minutes after the same meal each day to ensure consistent bioavailability. Swallow capsules whole; avoid crushing or chewing to prevent dose dumping.
* **Timing:** Administering the first dose at bedtime may help mitigate orthostatic changes.
* **Onset:** Symptomatic relief may be seen as early as 1 week, but clinical benefit is usually assessed at 2–4 weeks.
***
**Educational Disclaimer:** This information is for educational purposes and does not substitute for professional clinical judgment. Always verify current prescribing information, local institutional protocols, and patient-specific factors before administration.
